Biography

Jeffrey Tong is a partner with Third Rock Ventures. He has over 20 years in building and growing early-stage biotechnology companies. Prior to joining Third Rock, Dr. Tong was Executive Chairman of the board of Delinia (acquired by Celgene), was President and CEO of Nora Therapeutics, and a founding member of the management team at Infinity Pharmaceuticals. Over the course of his career, he has raised significant capital from both equity markets and pharma partnerships, led teams from preclinical through Phase 3 development, and developed integrated science/business strategies for building innovative biotechnology companies. Earlier in his career, Dr. Tong worked at McKinsey & Co. and was a founding researcher at the Harvard Bauer Center for Genomics Research. In addition to Septerna, he currently serves on the boards of Rapport Therapeutics, Maze Therapeutics, Asher Bio, ARTBIO, Marea Therapeutics, and Candid Therapeutics.

Dr. Tong received his educational training at the interface of molecular biology, organic chemistry and medicine and holds AB and MMS degrees from Harvard College and Harvard Medical School, respectively, as well as AM and PhD degrees from Harvard University.